Most pages listing selank benefits mix four things: one human brain-scan study in 52 adults, a handful of rat experiments, a Russian approval from 2009, and results that belong to a different peptide entirely.
The short answer. Russia approved Selank for generalized anxiety in 2009, but those trial papers are not in PubMed.
- The best Western human study is a 2020 fMRI scan in 52 healthy adults, measuring brain connectivity, not symptoms.
- The 39.6% drop in anxiety-like signs came from rats in a morphine-withdrawal model at 0.3 mg/kg.
- Immune and gut findings were measured in stressed rats, using cytokine panels and intestinal tissue.
Selank has one approved use anywhere. Russia cleared it for anxiety in 2009. Those trial papers are not in PubMed. The best Western study scanned 52 healthy adults. Rat work covers stress, immune signals and gut tissue. Western randomized trials number zero.
Which Selank benefits have human data?
Two of them, and only just. Everything else on the usual list is rodent work or borrowed.
Selank is a 7-amino-acid peptide. It joins tuftsin, a natural 4-residue human immune signal, to a 3-residue tail, Pro-Gly-Pro. That tail is there to slow breakdown, not to add an effect.
| Claimed benefit | Strongest study behind it | Who or what was measured |
|---|---|---|
| Less anxiety | Russian trials behind the 2009 registration | Humans, but the papers are not in PubMed |
| Changed brain network activity | Panikratova 2020, fMRI | 52 healthy adults |
| Easier opioid withdrawal | Konstantinopolsky 2022 | Rats, morphine withdrawal model |
| Immune or inflammation shift | Yasenyavskaya 2021 | Rats under “social” stress |
| Gut protection under stress | Mukhina 2020 | Rat large intestine |
| Calm without sedation | Animal behavior work and Russian claims | No Western randomized trial |
| Better memory or focus | Nothing found in PubMed | Zero human trials |
That is the whole map. The Selank complete guide covers the origin story; this page is about which claim rests on what.
The anxiety benefit: approved in Russia, unreadable in the West
This is the strongest claim, and it is also the one you cannot check. Russia's Ministry of Health approved Selank as nasal drops for generalized anxiety disorder in 2009. The label strength is 1.5 mg per mL.
The trials that supported that decision compared Selank against medazepam, a benzodiazepine. It compared well. Those documents are largely Russian-language and sit outside PubMed, so no one outside that system has read the raw data.
An approval is not a published trial. It means a regulator saw evidence. It does not mean you can open that evidence, check the sample size, or see who dropped out.
The closest thing to a mechanism-level anxiety result in a Western journal is animal work. A 2022 study in the Bulletin of Experimental Biology and Medicine used a morphine-withdrawal model in rats. Aversive, anxiety-like signs fell by 39.6% at 0.3 mg/kg, given into the abdomen.
Selank, a peptide analog of tuftsin, attenuates aversive signs of morphine withdrawal in rats.
Konstantinopolsky, Chernyakova & Kolik, Bulletin of Experimental Biology and Medicine, 2022 (study title)Note the species and the route. That is not a person, and it is not the nose. We break the trial record down in the Selank anxiety trials page.
The cognitive benefit: one scan, 52 people, 20 minutes
Selank is sold as a nootropic. No published human trial has measured memory, attention or test scores after giving it. What exists is a brain-imaging study.
Panikratova and colleagues, reporting in Doklady Biological Sciences in 2020, used functional connectivity mapping in 52 healthy adults. Network changes appeared within 5–20 minutes of a nasal dose, including in the right amygdala.
Functional connectomic approach to studying Selank and Semax effects.
Panikratova et al., Doklady Biological Sciences, 2020 (study title)- It is real human data. Something measurable happens in the brain, fast, after intranasal delivery.
- It is not a benefit. A shift in connectivity is a signal, not a symptom score or a cognitive test result.
- The participants were healthy. Nobody in that study had an anxiety diagnosis.
- It was acute. One session. No weeks-long arm, no follow-up, no placebo-controlled outcome measure.
Counting generously, the Western peer-reviewed literature naming Selank amounts to about 4 peer-reviewed Western studies. One of them is this scan.
Selank
The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.
Immune and gut benefits belong to stressed rats
Two of the more interesting claims come from a single Russian research line, and both were measured in rodents.
Yasenyavskaya and colleagues, writing in Current Reviews in Clinical and Experimental Pharmacology in 2021, looked at cytokines in animals under “social” stress. The panel included IL-1β, IL-6, TNF-α and TGF-β1 — the standard stress-linked inflammatory signals.
The influence of Selank on the level of cytokines under the conditions of “social” stress.
Yasenyavskaya et al., Current Reviews in Clinical and Experimental Pharmacology, 2021 (study title)Mukhina and colleagues, in the Bulletin of Experimental Biology and Medicine in 2020, went further downstream. They put rats through chronic restraint stress and examined the large intestine under a microscope. Selank was given at 100 µg/kg, and the tissue damage pattern changed.
A cytokine number moving in a rat is a mechanism finding. It is not an immune benefit in a person, and no human study has measured either endpoint.
The immune angle is not arbitrary. Tuftsin, the fragment Selank is built from, is an immune signaling peptide in its own right. The mechanism page covers the tuftsin and GABA pathways in detail.
Some Selank benefits actually belong to Semax
This is the trap. Selank and Semax came out of the same Moscow institute. Both are 7-residue peptides. Vendor pages and forum posts routinely merge their evidence, and Semax has far more of it.
- GABA receptor work. Vyunova and colleagues, 2023, tested synthetic corticotropins against the GABA-receptor system. Those are ACTH analogs, the Semax family, not Selank.
- Antidepressant-like effects. Inozemtseva and colleagues, 2024, reported these for Semax in a chronic unpredictable stress model in male rats.
- Stroke and gene expression. Filippenkov's group published immune-gene and expression profiling after experimental stroke, with figures such as ~1,171 genes shifted. Those studies are Semax, and Semax is the peptide Russia approved for ischemic stroke.
So when a product page says a Selank-class peptide “protects neurons after stroke,” the underlying papers usually have Semax in the title. Our Selank vs Semax comparison separates the two records, and the stack page explains why people run them together.
What has never been measured
Naming the absence is the useful part.
Western randomized controlled trials of Selank in PubMed: zero. No Phase III program exists in any indication, anywhere outside Russia. The two Russian anxiety trials everyone cites do not state a dose, a route or a course length in the versions available to Western readers.
There is also no published figure for how much of an intranasal dose is absorbed. That is the route Russia registered and the route the fMRI study used, and its bioavailability is simply not in the literature. See the nasal spray page and what the studies administered.
No human study has reported long-term safety, dependence liability, withdrawal, or interactions with prescribed anxiety medication. The frequently repeated claim that Selank calms without sedation or dependence comes from animal behavior work and the Russian record, not from a controlled human trial.
What to check before buying Selank
Because the benefit evidence is thin, the identity evidence matters more. A vial you cannot verify tells you nothing about what the studies did or did not show.
- Read the lot paperwork. A certificate of analysis should match the lot in your hand, not a sample lot from two years ago.
- Check legal status where you are. Russian approval is not US approval. Selank is not FDA approved. Our legality page sets out the research-use framing.
- Check testing rules if you compete. The WADA Prohibited List is updated yearly, and peptide categories move. Read the current list yourself rather than a vendor summary.
- Handle and store it properly. See storage temperature and reconstitution.
Selank vials commonly list around $56.99. Peptriva is the store this library sits beside; whichever source you use, the paperwork is the part worth reading first. Our buying guide covers what separates suppliers.
Selank
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- Russia approved Selank for generalized anxiety in 2009, but those trial papers are not in PubMed.
- The best Western human study is a 2020 fMRI scan in 52 healthy adults, measuring brain connectivity, not symptoms.
- The 39.6% drop in anxiety-like signs came from rats in a morphine-withdrawal model at 0.3 mg/kg.
- Immune and gut findings were measured in stressed rats, using cytokine panels and intestinal tissue.
- GABA-receptor, antidepressant and stroke results circulating as Selank benefits are largely Semax studies.
- Western randomized controlled trials of Selank number zero, and intranasal absorption has never been published.
What we're watching
Watch for benefit lists that cite stroke or neuroprotection data. Those papers almost always have Semax in the title, not Selank.
Frequently asked questions
What is Selank approved for?
Generalized anxiety disorder, in Russia only, since 2009. It was registered as 0.15% nasal drops, labeled at 1.5 mg per mL. It has no FDA approval and no European approval. In the US it is sold as a research compound, not a medicine.
Does Selank actually reduce anxiety?
The Russian trials behind the 2009 approval reported that it compared well with medazepam, a benzodiazepine. Those documents are not in PubMed and cannot be independently checked. In rats, a 2022 study measured a 39.6% fall in aversive withdrawal signs. No Western randomized trial has measured anxiety symptoms in people.
Is Selank a nootropic?
No published human study has tested memory, attention or task performance after Selank. The one human dataset is Panikratova 2020, a functional connectivity scan in 52 healthy adults, showing network changes within 5 to 20 minutes. A connectivity shift is a signal, not a cognitive score.
Does Selank cause sedation or dependence?
The claim that it does neither comes from animal behavior work and the Russian clinical record. No controlled human study has reported dependence liability, withdrawal, or long-term safety. That is an open question, not a settled one.
Why do Selank pages cite stroke research?
Because Selank and Semax came from the same Moscow institute and are both 7-residue peptides. The stroke, gene-expression and GABA-receptor papers are Semax studies. Semax is the one Russia approved for ischemic stroke. Mixing the two inflates Selank's record.
References
- Russian regulatory communications. (2009 onward.) Russian Ministry of Health approval of Selank as a nasal-drop formulation for generalized anxiety disorder. (Cited for regulatory context; primary trial documents are largely Russian-language and outside PubMed.) Russian Ministry of Health https://www.rosminzdrav.ru/
- Panikratova, Y. R., Lebedeva, I. S., Sokolov, O. Y., et al. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X
- Konstantinopolsky, M. A., Chernyakova, I. V., & Kolik, L. G. (2022). Selank, a peptide analog of tuftsin, attenuates aversive signs of morphine withdrawal in rats. Bulletin of Experimental Biology and Medicine, 173(6), 730–733. https://doi.org/10.1007/s10517-022-05624-x
- Yasenyavskaya, A. L., Samotrueva, M. A., Tsibizova, A. A., et al. (2021). The influence of Selank on the level of cytokines under the conditions of "social" stress. Current Reviews in Clinical and Experimental Pharmacology, 16(2), 162–167. https://doi.org/10.2174/1574884715666200704152810
- Mukhina, A. Y., Mishina, E. S., Bobyntsev, I. I., et al. (2020). Morphological changes in the large intestine of rats subjected to chronic restraint stress and treated with Selank. Bulletin of Experimental Biology and Medicine, 169(2), 281–285. https://doi.org/10.1007/s10517-020-04868-9
- Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., et al. (2023). Synthetic corticotropins and the GABA-receptor system: Direct and delayed effects. Chemical Biology & Drug Design, 101(6), 1393–1405. https://doi.org/10.1111/cbdd.14221
- Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Y., et al. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068. https://doi.org/10.1016/j.ejphar.2024.177068
- Filippenkov, I. B., Remizova, J. A., Stavchansky, V. V., et al. (2023). Synthetic adrenocorticotropic peptides modulate the expression pattern of immune genes in rat brain following the early post-stroke period. Genes, 14(7), 1382. https://doi.org/10.3390/genes14071382
- Filippenkov, I. B., Shpetko, Y. Y., Stavchansky, V. V., et al. (2024). ACTH-like peptides compensate rat brain gene expression profile disrupted by ischemia a day after experimental stroke. Biomedicines, 12(12), 2830. https://doi.org/10.3390/biomedicines12122830
- World Anti-Doping Agency. The Prohibited List 2026. https://www.wada-ama.org/en/prohibited-list